Encyclopedia of Clinical Neuropsychology

2018 Edition
| Editors: Jeffrey S. Kreutzer, John DeLuca, Bruce Caplan


  • Efrain Antonio GonzalezEmail author
Reference work entry
DOI: https://doi.org/10.1007/978-3-319-57111-9_9261

Generic Name


Brand Name



Antipsychotics, second generation, and mood stabilizer

Proposed Mechanism(s) of Action

Combination of central dopamine D2 and serotonin 5-HT2A receptor antagonism (sublingual)


For the treatment of schizophrenia and manic or mixed bipolar 1 episodes.

Off-Label Use

Agitation associated with a myriad of psychiatric conditions and dementia. Borderline personality disorder. Disruptive behavioral disorders associated with childhood.

Side Effects


Increased risk of mortality in elderly patients with dementia-related psychosis, mania. Extrapyramidal symptoms, prolongation of QT interval, and agranulocytosis.


  • Headache, dizziness, somnolence, dry mouth, nausea, tachycardia, diarrhea, orthostatic hypotension, and weight gain

References and Readings

  1. Cutler, A. J., Kalali, A. H., Weiden, P. J., Hamilton, J., & Wolfgang, C. D. (2008). Four-week, double-blind, placebo- and ziprasidone-controlled trial of iloperidone in patients with acute exacerbations of schizophrenia. Journal of Clinical Psychopharmacology, 28(2 Suppl 1), S20–S28.PubMedCrossRefGoogle Scholar
  2. Kane, J. M., Lauriello, J., Laska, E., Di Marino, M., & Wolfgang, C. D. (2008). Long-term efficacy and safety of iloperidone: Results from 3 clinical trials for the treatment of schizophrenia. Journal of Clinical Psychopharmacology, 28(2 Suppl 1), S29–S35.PubMedCrossRefGoogle Scholar
  3. Kongsamut, S., Roehr, J. E., Cai, J., Hartman, H. B., Weissensee, P., Kerman, L. L., Tang, L., & Sandrasagra, A. (1996). Iloperidone binding to human and rat dopamine and 5-HT receptors. European Journal of Pharmacology, 317(2–3), 417–423.CrossRefGoogle Scholar
  4. Physicians’ desk reference (71st ed.) (2017). Montvale: Thomson PDR.Google Scholar
  5. Potkin, S. G., Litman, R. E., Torres, R., & Wolfgang, C. D. (2008). Efficacy of iloperidone in the treatment of schizophrenia: Initial phase 3 studies. Journal of Clinical Psycopharmacology, 28(2 Suppl 1), S4–11.CrossRefGoogle Scholar
  6. Sainati, S. M., Hubbard, J. W., Chi, E., Grasing, K., & Brecher, M. B. (1995). Safety, tolerability, and effect of food on the pharmacokinetics of iloperidone (HP 873), a potential atypical antipsychotic. Journal of Clinical Pharmacology, 35(7), 713–720.CrossRefGoogle Scholar
  7. Stahl, S. M. (2007). Essential psychopharmacology: The prescriber’s guide (2nd ed.). New York: Cambridge University Press.Google Scholar
  8. Szczepanik, A. M., Brougham, L. R., Roehr, J. E., Conway, P. G., Ellis, D. B., & Wilmot, C. A. (1996). Ex vivo studies with iloperidone (HP 873), a potential atypical antipsychotic with dopamine D2/5-hydroxytryptamine2 receptor antagonist activity. The Journal of Pharmacology and Experimental Therapeutics, 278(2), 913–920.Google Scholar
  9. Weiden, P. J., Cutler, A. J., Polymeropoulos, M. H., & Wolfgang, C. D. (2008). Safety profile of iloperidone: A pooled analysis of 6-week acute-phase pivotal trials. Journal of Clinical Psychopharmacology, 28(2 Suppl 1), S12–S19.PubMedCrossRefGoogle Scholar

Additional Information

  1. Free Drug Online. www.medscape.com.
  2. Free Drug Online and PDA Software. www.epocrates.com.

Copyright information

© Springer International Publishing AG, part of Springer Nature 2018

Authors and Affiliations

  1. 1.College of Psychology, Nova Southeastern UniversityFort LauderdaleUSA
  2. 2.Utah State UniversityLoganUSA